


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app19.us.archive.org';v.server_ms=587;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Combined hormonal contraception and the risk of venous thromboembolism: a guideline. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712211419im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712211419im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712211419im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712211419im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712211419/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712211419im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712211419cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712211419js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712211419if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712211419/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712211419if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712211419/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712211419/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712211419/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712211419/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712211419/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712211419/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712211419/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712211419/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712211419/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712211419/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712211419/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712211419/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712211419/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712211419/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712211419/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712211419/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712211419/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712211419/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712211419/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712211419/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712211419/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712211419/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712211419/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712211419/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712211419/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:011145</li>
            <li>2017 Jan
            </li>            
                                </ul>
        <div>
                <h1>Combined hormonal contraception and the risk of venous thromboembolism: a guideline.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712211419/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20Society%20for%20Reproductive%20Medicine&amp;fLockTerm=American%2BSociety%2Bfor%2BReproductive%2BMedicine">American Society for Reproductive Medicine</a></li>
                        <li>   
                                <a id="86" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017 Jan;107(1):43-51. [91 references] <a href="https://web.archive.org/web/20180712211419/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27793376" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712211419im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180712211419/https://www.guideline.gov/Home/Disclaimer?id=50627&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fwww.asrm.org%252fglobalassets%252fasrm%252fasrm-content%252fnews-and-publications%252fpractice-guidelines%252ffor-non-members%252fcombined_hormonal_contraception_vte-pdfnoprint.pdf">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712211419im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180712211419/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
                        <li><a href="/web/20180712211419/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
                        <li><a href="/web/20180712211419/https://www.guideline.gov/search?f_Age_of_Target_Population=Adolescent%20%2813%20to%2018%20years%29&amp;fLockTerm=Adolescent%2B%2813%2Bto%2B18%2Byears%29">Adolescent (13 to 18 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180712211419/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">HCPCS</h5>
                    <div class="field-content">
<a href="/web/20180712211419/https://www.guideline.gov/search?f_HCPCS_CUI=C1509018&amp;fLockTerm=Contraceptive+supply%2c+hormone+containing+patch%2c+each">Contraceptive supply, hormone containing patch, each</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0009906&amp;fLockTerm=Contraceptives%2c+Oral%2c+Combined">Contraceptives, Oral, Combined</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0009907&amp;fLockTerm=Contraceptives%2c+Oral%2c+Hormonal">Contraceptives, Oral, Hormonal</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0014939&amp;fLockTerm=Estrogens">Estrogens</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0023566&amp;fLockTerm=Levonorgestrel">Levonorgestrel</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0025345&amp;fLockTerm=Menstruation+Disturbances">Menstruation Disturbances</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0028356&amp;fLockTerm=Norethindrone">Norethindrone</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0041747&amp;fLockTerm=Pregnancy%2c+Unplanned">Pregnancy, Unplanned</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0033306&amp;fLockTerm=Progestins">Progestins</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C0991556&amp;fLockTerm=Transdermal+Patch">Transdermal Patch</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MSH_CUI=C1861172&amp;fLockTerm=Venous+Thromboembolism">Venous Thromboembolism</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0009906&amp;fLockTerm=Combined+Oral+Contraceptives">Combined Oral Contraceptives</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0043822&amp;fLockTerm=drospirenone">drospirenone</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0014939&amp;fLockTerm=Estrogens">Estrogens</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0025345&amp;fLockTerm=Menstruation+Disturbances">Menstruation Disturbances</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0028356&amp;fLockTerm=Norethindrone">Norethindrone</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0994894&amp;fLockTerm=Patch+Dosage+Form">Patch Dosage Form</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C3536710&amp;fLockTerm=Progestin+%5bEPC%5d">Progestin [EPC]</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0033306&amp;fLockTerm=Progestins">Progestins</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C3496592&amp;fLockTerm=Risk+for+venous+thromboembolism">Risk for venous thromboembolism</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0991556&amp;fLockTerm=Transdermal+System">Transdermal System</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0041747&amp;fLockTerm=Unplanned+pregnancy">Unplanned pregnancy</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C0042260&amp;fLockTerm=Vaginal+Ring">Vaginal Ring</a>
, <a href="/web/20180712211419/https://www.guideline.gov/search?f_MTH_CUI=C1861172&amp;fLockTerm=Venous+Thromboembolism">Venous Thromboembolism</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C2732751&amp;fLockTerm=Assessment+of+risk+of+venous+thromboembolism">Assessment of risk of venous thromboembolism</a>
 (443749004), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009906&amp;fLockTerm=Combined+oral+contraceptive">Combined oral contraceptive</a>
 (346388008), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025345&amp;fLockTerm=Disorder+of+menstruation">Disorder of menstruation</a>
 (289896006), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025345&amp;fLockTerm=Disorder+of+menstruation">Disorder of menstruation</a>
 (386804004), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0043822&amp;fLockTerm=Drospirenone">Drospirenone</a>
 (395275003), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0043822&amp;fLockTerm=Drospirenone">Drospirenone</a>
 (410919000), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0014939&amp;fLockTerm=Estrogen">Estrogen</a>
 (41598000), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0014939&amp;fLockTerm=Estrogen">Estrogen</a>
 (61946003), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0023566&amp;fLockTerm=Levonorgestrel">Levonorgestrel</a>
 (109032009), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0023566&amp;fLockTerm=Levonorgestrel">Levonorgestrel</a>
 (126109000), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0028356&amp;fLockTerm=Norethindrone">Norethindrone</a>
 (126102009), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0028356&amp;fLockTerm=Norethindrone">Norethindrone</a>
 (63758001), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0994894&amp;fLockTerm=Patch">Patch</a>
 (419702001), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0994894&amp;fLockTerm=Patch">Patch</a>
 (739003001), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033306&amp;fLockTerm=Progestin+preparation">Progestin preparation</a>
 (116614001), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033306&amp;fLockTerm=Progestin+preparation">Progestin preparation</a>
 (20249007), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0991556&amp;fLockTerm=Prolonged-release+transdermal+patch">Prolonged-release transdermal patch</a>
 (385114002), <a href="/web/20180712211419/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041747&amp;fLockTerm=Unplanned+pregnancy">Unplanned pregnancy</a>
 (83074005)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#430" class="section-mark">Contraindications</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/downloadcontent/ngc-11145?contentType=pdf" class="pdf">.PDF 94.9 kb</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/downloadcontent/ngc-11145?contentType=word" class="word">Word Document 286.4 kb</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/downloadcontent/ngc-11145?contentType=xml" class="xml">.XML 36.7 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712211419/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712211419/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712211419/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712211419/mailto:/?Subject=AHRQ: Combined hormonal contraception and the risk of venous thromboembolism: a guideline.&amp;body=https://www.guideline.gov/summaries/summary/50627/combined-hormonal-contraception-and-the-risk-of-venous-thromboembolism-a-guideline" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Combined hormonal contraception and the risk of venous thromboembolism: a guideline. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2017 Jan 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/citedownload/50627?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/citedownload/50627?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/citedownload/50627?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/citedownload/50627?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/citedownload/50627?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/citedownload/50627">RefWorks</a></li>
                            <li><a href="/web/20180712211419/https://www.guideline.gov/summaries/citedownload/50627?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="50627" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Definitions for the level of the evidence (<strong>Level I-III</strong>) and strength of the recommendations (<strong>Grade A-C</strong>) are given at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Does the Dose of Estrogen Affect Venous Thromboembolism (VTE) Rates?</span></strong></p>
<p><strong>Summary Statement</strong></p>
<p>There are no randomized trials large enough to compare thrombosis risk in patients on oral contraceptives containing different doses of ethinyl estradiol (EE). Only level II-2 studies exist, including large cohort and case-control studies. It is difficult to compare the effect of the EE dose since preparations differ with respect to the progestin component. In addition, observational studies are limited by a number of unmeasured confounders and bias. The following may be concluded from the literature:</p>
<ul style="list-style-type: disc;">
    <li>While no longer available in the United States, high-dose combined oral contraception (COC) (&gt;50 &micro;g) is associated with higher risks of VTE than lower-dose formulations. (<strong>Grade B</strong>) </li>
    <li>There is fair evidence that combined oral contraception with 50 &micro;g EE has a higher risk of thrombosis compared with sub-50 &micro;g EE formulations. (<strong>Grade B</strong>). However, data are conflicting and difficult to interpret due to the variable progestin component of the pills studied. </li>
    <li>There is fair evidence that COCs containing EE doses lower than 35 &micro;g have similar VTE risk to 35 &micro;g formulations. (<strong>Grade B</strong>) </li>
</ul>
<p><strong><span style="text-decoration: underline;">Does Type of Progestin Contribute to VTE Risk?</span></strong></p>
<p><strong>Summary Statement</strong></p>
<p>There are no randomized trials large enough to compare the risk of VTE in patients on different types of oral contraceptives. Only level II-2 studies exist, including large cohort and case-control studies. It is difficult to compare the effect of the progestin component alone, as some studies include preparations with different doses of EE. In addition, observational studies are limited by a number of confounders and bias (including differences in users and non-users of COCs, duration of combined oral contraception use, and misclassification of VTE due to differences in diagnostic criteria used).</p>
<p>Because of the lack of high-quality level I studies comparing progestins, it is possible that methodological problems in the present studies are responsible for the small increased risk in VTE events, and that there is actually no increased risk with third- or fourth-generation progestins, such as desogestrel or drospirenone. If there is indeed an increased relative risk (RR), the absolute risk increase is extremely small. Therefore, in the appropriately selected patient, the choice of COC method does not need to be made based on the type of progestin. If a woman has estrogen-related COC risk for VTE, then no route of administration or dose of estrogen has been found to be safer. All estrogen-containing hormonal methods are contraindicated in that setting.</p>
<ul style="list-style-type: disc;">
    <li>There is fair evidence that all available combined hormonal contraceptive (CHC) preparations increase the risk of VTE over the non-pregnant state. </li>
    <li>There is fair evidence that women using preparations of COC with drospirenone or third-generation progestins have a slightly higher risk of VTE compared with those using norethindrone or levonorgestrel. (<strong>Grade B</strong>). These results may in part be related to characteristics of the populations using these preparations. </li>
</ul>
<p><strong><span style="text-decoration: underline;">Does Route of Administration of CHC Contribute to VTE Risk?</span></strong></p>
<p><strong>Summary Statement</strong></p>
<p>All of the studies addressing this question were level II-III.</p>
<p>There is insufficient evidence that the contraceptive patch or contraceptive vaginal ring has a different risk of VTE compared with COCs. (<strong>Grade C</strong>)</p>
<p><strong><span style="text-decoration: underline;">Are Smoking, Obesity, or Inherited Thrombophilias Risk Factors for VTE in CHC Users?</span></strong></p>
<p><strong>Summary Statement</strong></p>
<p>Several level II and III studies have identified risk factors associated with VTE; however, determining to what degree a specific risk factor increases the risk of VTE is difficult as these studies are heterogeneous and are often confounded by biases.</p>
<ul style="list-style-type: disc;">
    <li>There is fair evidence that tobacco use, age (&gt;35 years), obesity, and the presence of hereditary thrombophilias (including factor V Leiden mutation, prothrombin G20210A mutation and protein C, protein S, or antithrombin deficiency) increase the risk of thrombotic events in the setting of CHC use. (<strong>Grade B</strong>) </li>
</ul>
<p><strong><span style="text-decoration: underline;">Recommendation</span></strong></p>
<p>In the patient in whom combined hormonal contraception is appropriate, it is reasonable to use any currently available preparation.</p>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong></p>
<p><strong>Level of Evidence</strong></p>
<p><strong>Level I</strong>: Evidence obtained from at least one properly designed randomized, controlled trial.</p>
<p><strong>Level II-1</strong>: Evidence obtained from well-designed controlled trials without randomization.</p>
<p><strong>Level II-2</strong>: Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.</p>
<p><strong>Level II-3</strong>: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.</p>
<p><strong>Level III</strong>: Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.</p>
<p><strong>Strength of Recommendations</strong></p>
<p><strong>Grade A</strong>: There is good evidence to support the recommendations, either for or against.</p>
<p><strong>Grade B</strong>: There is fair evidence to support the recommendations, either for or against.</p>
<p><strong>Grade C</strong>: There is insufficient evidence to support the recommendations, either for or against.</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Unintended pregnancy </li>
    <li>Menstrual disorders </li>
</ul></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Prevention</p>
                    <p>Risk Assessment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Family Practice</p>
                    <p>Internal Medicine</p>
                    <p>Obstetrics and Gynecology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To evaluate the association between combined hormonal contraception (CHC) and the risk of venous thromboembolism (VTE)</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Women using combined hormonal contraception (CHC)</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;" start="1">
    <li>Dose of estrogen used </li>
    <li>Type of progestin used (drospirenone or&nbsp;third-generation progestin versus norethindrone or levonorgestrel) </li>
    <li>Route of administration of combined hormonal contraception (CHC) (e.g., contraceptive patch or contraceptive vaginal ring versus oral pill) (<em>insufficient evidence to make a recommendation</em>) </li>
    <li>Assessment of risk factors for venous thromboembolism (e.g., smoking, obesity, inherited thrombophilias) </li>
</ol></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Relative and absolute risk of venous thromboembolism (VTE) </li>
    <li>VTE rates </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Hand-searches of Published Literature (Primary Sources)</p>
                    <p>Hand-searches of Published Literature (Secondary Sources)</p>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Literature Search</span></strong></p>
<p>A systematic literature search of relevant articles was performed in the electronic database MEDLINE through PubMed (February and June 2015), with a filter for human subject research.</p>
<p>A combination of the medical subject headings or text words/keywords were used: birth control; contraception; combined hormonal contraception; combined oral contraceptive; combined oral contraceptives; contraceptives, oral; contraceptives, oral/administration and dosage; contraceptives, oral, combined; contraceptives, oral, combined/administration and dosage; hormonal contraception; oral contraceptive; oral contraceptives; desogestrel; drospirenone; estradiol; estrogen; oestrogen; ethynodiol diacetate; etynodiol diacetate; levonorgestrel; nomegestrol; norethisterone; norethisteron; norethindrone; norethindron; norethynodrel; norgestimat; norgestimate; norgestrel; AND ethinyl estradiol; ethinyl estradiol; ethinylestradiol; mestranol; progesterone; progestin; progestins; progestogen; progestogens; AND cerebral vein thrombosis; clot; deep vein thrombosis; deep venous thrombosis; DVT; embolism; hepatic thrombosis; mesenteric venous thrombosis; pulmonary emboli*; pulmonary embolism; thrombosis; thrombus; thromboembolism; thrombophlebitis; vein embolism; vein thrombosis; venous embolism; venous thromboembolism; venous thrombosis; venous thrombosis; venous thrombotic; first generation, second generation, third generation, fourth generation; AND obese; obesity; body weight; body weight; body mass index; BMI; PCOS; polycystic ovaries; polycystic ovary; polycystic ovary syndrome; polycystic ovarian syndrome; smoking; age; risk, risks, risk factor, risk factors.</p>
<p><strong><span style="text-decoration: underline;">Inclusion/Exclusion Criteria</span></strong></p>
<table border="1" cellspacing="1" cellpadding="3" summary="Table: Inclusion/Exclusion Criteria">
    <thead>
        <tr>
            <th width="50%" valign="top" scope="col">Include</th>
            <th width="50%" valign="top" scope="col">Exclude</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign="top">Level 1, 2-1, 2-2 studies; 2-3</td>
            <td valign="top">Case reports, reviews, opinions, off topic</td>
        </tr>
        <tr>
            <td valign="top">Human studies</td>
            <td valign="top">Animal studies</td>
        </tr>
        <tr>
            <td valign="top">English</td>
            <td valign="top">Non-English</td>
        </tr>
        <tr>
            <td valign="top">Limit to products available in the USA only</td>
            <td valign="top">Gestodene and cyproterone acetate-containing product</td>
        </tr>
        <tr>
            <td valign="top">Combined contraception only</td>
            <td valign="top">Progestin-only preparations</td>
        </tr>
        <tr>
            <td valign="top">Venous events only</td>
            <td valign="top">Stroke, coronary/heart attack, arterial</td>
        </tr>
        <tr>
            <td valign="top">Oral, vaginal, transdermal OR patch</td>
            <td valign="top">Barrier, injectable</td>
        </tr>
        <tr>
            <td valign="top">Co-factors: include smoking; obesity; polycystic ovary syndrome (PCOS); inherited thrombophilias</td>
            <td valign="top">In vitro fertilization (IVF)</td>
        </tr>
        <tr>
            <td valign="top">Reproductive-age women</td>
            <td valign="top">Peri- and postmenopausal women; menopausal hormone therapy</td>
        </tr>
        <tr>
            <td valign="top">&nbsp;</td>
            <td valign="top">Hormone-replacement therapy (HRT) patients</td>
        </tr>
        <tr>
            <td valign="top">&nbsp;</td>
            <td valign="top">Emergency contraception</td>
        </tr>
        <tr>
            <td valign="top">&nbsp;</td>
            <td valign="top">Surrogate markers</td>
        </tr>
    </tbody>
</table>
<p>An independent panel of experts reviewed the full articles of all citations that possibly matched the predefined selection criteria. Final inclusion or exclusion decisions were made on examination of the articles in full. Disagreements about inclusion among reviewers were discussed and solved by consensus or arbitration after consultation with an independent reviewer/epidemiologist. Studies were eligible if they met one of the following criteria: primary evidence (clinical trials) that assessed the effectiveness of a treatment correlated with an outcome measure (VTE); meta-analyses; and relevant articles from bibliographies of identified articles.</p>
<p>Systematic reviews/meta-analyses were individually considered and included if they followed a strict methodological process and assessed relevant evidence.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>The electronic search and examination of reference lists from primary and review articles yielded 1,254 studies, of which 86 studies were included.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Level of Evidence</span></strong></p>
<p><strong>Level I</strong>: Evidence obtained from at least one properly designed randomized, controlled trial.</p>
<p><strong>Level II-1</strong>: Evidence obtained from well-designed controlled trials without randomization.</p>
<p><strong>Level II-2</strong>: Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.</p>
<p><strong>Level II-3</strong>: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.</p>
<p><strong>Level III</strong>: Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Review of Published Meta-Analyses</p>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>The quality of the evidence for each reference in the bibliography (see the original guideline document) was evaluated using the grading system found in the "Rating Scheme for the Strength of the Evidence" field.</p>
<p>Systematic reviews/meta-analyses were individually considered and included if they followed a strict methodological process and assessed relevant evidence.</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Questions</span></strong></p>
<p>The literature was reviewed to answer the following questions:</p>
<ol style="list-style-type: decimal;" start="1">
    <li>Does type of progestin affect venous thromboembolism (VTE) rates? </li>
    <li>Is route of OCP (oral contraception pills) administration (patch, oral, vaginal) a co-factor for VTE? </li>
    <li>Does the dose of estrogen (&lt;35 mcg vs &gt;35 mcg) in OCPs affect VTE rates? </li>
    <li>Are smoking, obesity, PCOS, or inherited thrombophilias co-factors for VTE in women taking OCPs? </li>
</ol></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Strength of Recommendations</span></strong></p>
<p><strong>Grade A</strong>: There is good evidence to support the recommendations, either for or against.</p>
<p><strong>Grade B</strong>: There is fair evidence to support the recommendations, either for or against.</p>
<p><strong>Grade C</strong>: There is insufficient evidence to support the recommendations, either for or against.</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>This document was reviewed by American Society for Reproductive Medicine members, and their input was considered in the preparation of the final document. The Practice Committee and the Board of Directors
of the American Society for Reproductive Medicine have approved this report.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each summary statement that supports the recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>The benefits of any currently available combined oral contraceptive to prevent pregnancy outweigh the risks for most women. When selecting a particular combined hormonal contraceptive preparation, any potential risk of venous thromboembolism should be balanced with the potential benefits associated with each preparation.</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>Combined oral contraceptives increase the risk of venous thromboembolism (VTE). Women taking preparations containing drospirenone and third-generation progestins appear to be at slightly increased risk of VTE compared with those taking first- and second-generation preparations.</p></div></p>

            </div>
                <h2 id="430" class="accordion-title section-430 is-active" role="tab" aria-expanded="true"><a href="#">Contraindications</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Contraindications</a></h3>
                    <p><div class="content_para"><p>If a woman has estrogen-related combined oral contraception (COC) risk for venous thromboembolism (VTE), then no route of administration or dose of estrogen has been found to be safer. All estrogen-containing hormonal methods are contraindicated in that setting.</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. </li>
    <li>There are no large, prospective randomized studies comparing the risk of venous thromboembolism (VTE) among various doses of estrogen, types of progestin, or routes of administration. Only level II-2 studies exist, including large cohort and case-control studies that are limited by a number of methodological issues which may skew results. For example, without randomization, it is difficult to control for different patient populations and prescriber bias. It is also important to recognize that VTE risk is greater in new hormonal contraceptive users during the first year, in older women, and in obese women. Many studies do not adequately account for imbalances in these risk factors between treatment groups. In addition, the diagnosis of venous thrombosis may not always be accurate in studies since cases are not always confirmed by hospital records or radiologic studies. Finally, given that the incidence of VTE is low, large numbers of observations are required to compare cases among various treatment groups. </li>
</ul></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Staff Training/Competency Material</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Staying Healthy</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Patient-centeredness</p>
                    <p>Safety</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017 Jan;107(1):43-51. [91 references] <a href="https://web.archive.org/web/20180712211419/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27793376" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180712211419im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2017 Jan</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>American Society for Reproductive Medicine - Nonprofit Organization</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>American Society for Reproductive Medicine</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Practice Committee of the American Society for Reproductive Medicine</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Committee Members</em>: Samantha Pfeifer, MD; Samantha Butts, MD, MSCE; Daniel Dumesic, MD; Gregory Fossum, MD; Clarisa Gracia, MD, MSCE; Andrew La Barbera, PhD; Jennifer Mersereau, MD; Randall Odem, MD; Alan Penzias, MD; Margareta Pisarska, MD; Robert Rebar, MD; Richard Reindollar, MD; Mitchell Rosen, MD; Jay Sandlow, MD; Rebecca Sokol, MD, MPH; Michael Vernon, PhD; Eric Widra, MD</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available from the <a href="/web/20180712211419/https://www.guideline.gov/Home/Disclaimer?id=50627&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.asrm.org%2fglobalassets%2fasrm%2fasrm-content%2fnews-and-publications%2fpractice-guidelines%2ffor-non-members%2fcombined_hormonal_contraception_vte-pdfnoprint.pdf" title="American Society for Reproductive Medicine Web site">American Society for Reproductive Medicine Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712211419im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>Continuing medical education (CME) credit related to this guideline is available from the <a href="/web/20180712211419/https://www.guideline.gov/Home/Disclaimer?id=50627&amp;contentType=summary&amp;redirect=https%3a%2f%2fstore.asrm.org%2fLearn%2fFindACourse.aspx" title="American Society for Reproductive Medicine Web site">American Society for Reproductive Medicine Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712211419im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on March 27, 2017. The information was verified by the guideline developer on April 17, 2017.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712211419/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712211419/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712211419/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712211419/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712211419/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712211419/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712211419/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712211419/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712211419/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712211419/https://www.guideline.gov/disclaimer?id=50627&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712211419/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712211419/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712211419/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712211419/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712211419/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712211419/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712211419/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712211419/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712211419/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712211419/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712211419/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712211419/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712211419/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712211419/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712211419im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712211419/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712211419/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712211419js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712211419js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 21:14:19 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:53:00 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 397.47 (3)
  esindex: 0.01
  captures_list: 424.348
  CDXLines.iter: 21.433 (3)
  PetaboxLoader3.datanode: 58.991 (4)
  exclusion.robots: 0.226
  exclusion.robots.policy: 0.211
  RedisCDXSource: 1.236
  PetaboxLoader3.resolve: 441.632 (2)
  load_resource: 138.725
-->